From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice
Abstract
:1. Introduction
2. Patients and Methods
3. Statistics
4. Results
5. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- WHO. Combating Hepatitis B and C to Reach Elimination by 2030; World Health Organization: Geneva, Switzerland, 2016; Available online: https://apps.who.int/iris/handle/10665/206453 (accessed on 25 July 2016).
- Bundesministerium für Gesundheit; Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung. Strategie zur Eindämmung von HIV, Hepatitis B und C und anderen sexuell übertragbaren Infektionen. BIS 2030—bedarfsorientiert, integriert, sektorübergreifend. Beschluss Bundeskabinetts 2016, 6, 1–28. [Google Scholar]
- Razavi, H.; Sanchez, G.Y.; Yuen, C.; Cornberg, M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2019, 40, 522–529. [Google Scholar] [CrossRef] [PubMed]
- Razavi, H.; Waked, I.; Sarrazin, C.; Myers, R.P.; Idilman, R.; Calinas, F.; Estes, C. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J. Viral Hepat. 2014, 21 (Suppl. S1), 34–59. [Google Scholar] [CrossRef] [PubMed]
- Huppe, D.; Serfert, Y.; Buggisch, P.; Mauss, S.; Boker, K.H.W.; Muller, T.; Wedemeyer, H. 4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R). Z. Gastroenterol. 2019, 57, 27–36. [Google Scholar] [PubMed]
- Wolffram, I.; Petroff, D.; Batz, O.; Jedrysiak, K.; Kramer, J.; Tenckhoff, H.; Wiegand, J. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J. Hepatol. 2015, 62, 1256–1264. [Google Scholar] [CrossRef] [PubMed]
- Robert Koch Institut. Virushepatitis B und D sowie Virushepatitis C im Jahr 2019. Epid. Bull. 2020, 30, 1–36. [Google Scholar]
- Lullau, A.; Petroff, D.; Batz, O.; Kramer, J.; Jedrysiak, K.; Tenckhoff, H.; Wiegand, J. Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. Eur. J. Gastroenterol. Hepatol. 2018, 30, 280–283. [Google Scholar] [CrossRef] [PubMed]
- Citarella, A.; Cammarota, S.; Bernardi, F.F.; Coppola, C.; D’Anto, M.; Fogliasecca, M.; Persico, M. Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy. Life 2020, 10, 359. [Google Scholar] [CrossRef] [PubMed]
- Sarrazin, C.; Zimmermann, T.; Berg, T.; Hinrichsen, H.; Mauss, S.; Wedemeyer, H.; Deutsche, A.I.D.S.Z. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion. Z. Gastroenterol. 2020, 58, 1110–1131. [Google Scholar] [CrossRef] [PubMed]
- Screening auf Hepatitis B und C neuer Bestandteil des Gesundheits-Check-Ups: Gemeinsamer Bundesausschuss. 2020. Available online: https://www.aerzteblatt.de/nachrichten/118435/Screening-auf-Hepatitis-B-und-C-neuer-Bestandteil-des-Gesundheits-Check-ups (accessed on 28 September 2021).
- Byrd, J.C.; Moskowitz, M.A. Outpatient consultation: Interaction between the general internist and the specialist. J. Gen. Intern. Med. 1987, 2, 93–98. [Google Scholar] [CrossRef] [PubMed]
- Bourguet, C.; Gilchrist, V.; McCord, G. The consultation and referral process. A report from NEON. Northeastern Ohio Network Research Group. J. Fam. Pract. 1998, 46, 47–53. [Google Scholar] [PubMed]
- Hacker, K.A.; Weintraub, T.A.; Fried, L.E.; Ashba, J. Role of school-based health centers in referral completion. J. Adolesc. Health 1997, 21, 328–334. [Google Scholar] [CrossRef]
- Forrest, C.B.; Shadmi, E.; Nutting, P.A.; Starfield, B. Specialty referral completion among primary care patients: Results from the ASPN Referral Study. Ann. Fam. Med. 2007, 5, 361–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adamson, P.C.; Miceli, J.; Shiferaw, B.; Villanueva, M.S.; Canterino, J.E. A Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population. Am. J. Med. 2020, 133, 705–712. [Google Scholar] [CrossRef] [PubMed]
- Petroff, D.; Bätz, O.; Jedrysiak, K.; Kramer, J.; Berg, T.; Wiegand, J. The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings. Viruses 2021, 13, 2327. [Google Scholar] [CrossRef] [PubMed]
Total (n = 1875) | Anti-HCV Negative (n = 1863) | Anti-HCV Positive (n = 12) | p-Value | |
---|---|---|---|---|
Age (years) | 50.4 ± 16.6 | 50.4 ± 16.7 | 46.9 ± 11.7 | 0.32 |
≤40 | 639 (34%) | 635 (34%) | 4 (33%) | 1.00 |
40–60 | 666 (36%) | 659 (35%) | 7 (58%) | 0.13 |
>60 | 570 (30%) | 569 (31%) | 1 (8%) | 0.12 |
Male | 856 (46%) | 849 (46%) | 7 (58%) | 0.40 |
Elevated ALT | 214 (11%) | 212 (11%) | 2 (17%) | 0.64 |
Elevated AST | 99 (5%) | 98 (5%) | 1 (8%) | 0.48 |
Elevated GGT | 241 (13%) | 240 (13%) | 1 (8%) | 1.00 |
Known elevated liver blood tests | 157 (8%) | 152 (8%) | 5 (42%) | 0.0019 |
Fatigue, impaired concentration, upper abdominal pain | 597 (32%) | 594 (32%) | 3 (25%) | 0.76 |
Medical profession | 107 (6%) | 107 (6%) | 0 (0%) | 1.00 |
Blood transfusion before 1992 | 91 (5%) | 90 (5%) | 1 (8%) | 0.45 |
Organ transplantation | 16 (1%) | 16 (1%) | 0 (0%) | 1.00 |
Operation | 1157 (62%) | 1148 (62%) | 9 (75%) | 0.39 |
Piercing | 255 (14%) | 254 (14%) | 1 (8%) | 1.00 |
Tattoo | 353 (19%) | 348 (19%) | 5 (42%) | 0.057 |
IV drug users | 17 (1%) | 12 (1%) | 5 (42%) | <0.001 |
Known HCV | 9 (0%) | 7 (0%) | 2 (17%) | 0.0013 |
Household member or family with HCV | 41 (2%) | 41 (2%) | 0 (0%) | 1.00 |
HCV therapy in past | 16 (1%) | 10 (1%) | 6 (50%) | <0.001 |
Serious kidney disease | 6 (0%) | 5 (0%) | 1 (8%) | 0.038 |
You or parents from high risk country | 258 (14%) | 254 (14%) | 4 (33%) | 0.070 |
Travel to high risk country | 412 (22%) | 410 (22%) | 2 (17%) | 1.00 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Petroff, D.; Bätz, O.; Jedrysiak, K.; Lüllau, A.; Kramer, J.; Möller, H.; Heyne, R.; Jäger, B.; Berg, T.; Wiegand, J. From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice. Pathogens 2021, 10, 1570. https://doi.org/10.3390/pathogens10121570
Petroff D, Bätz O, Jedrysiak K, Lüllau A, Kramer J, Möller H, Heyne R, Jäger B, Berg T, Wiegand J. From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice. Pathogens. 2021; 10(12):1570. https://doi.org/10.3390/pathogens10121570
Chicago/Turabian StylePetroff, David, Olaf Bätz, Katrin Jedrysiak, Anja Lüllau, Jan Kramer, Hjördis Möller, Renate Heyne, Burkhard Jäger, Thomas Berg, and Johannes Wiegand. 2021. "From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice" Pathogens 10, no. 12: 1570. https://doi.org/10.3390/pathogens10121570
APA StylePetroff, D., Bätz, O., Jedrysiak, K., Lüllau, A., Kramer, J., Möller, H., Heyne, R., Jäger, B., Berg, T., & Wiegand, J. (2021). From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice. Pathogens, 10(12), 1570. https://doi.org/10.3390/pathogens10121570